← brief for 2026-11-03 · Slowing decline

Changes in Metabolic and Blood Pressure Outcomes With Semaglutide Across Chronic Kidney Disease Stages: A Post Hoc Analysis of the FLOW Trial.

Article A Peer reviewed Meta-analysis or large trial

Key takeaways

This is a follow-up analysis of a large randomized trial called FLOW. It looked at how a drug called semaglutide affected blood sugar, weight, and blood pressure in people with kidney disease. The study checked these effects across different stages of kidney damage. This is a large trial, so the evidence is strong.

Who did this work

Friedman AN · Basile J · Busch R · Charytan DM · Mahaffey KW · Mehanna S · Rasmussen S · Rossing P · Swift C · Tuttle KR · Pratley R

Source

Article · PubMed, the drug frontier · 2026 Nov 3
https://pubmed.ncbi.nlm.nih.gov/42977539/